share_log

NexImmune | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

NexImmune | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

NexImmune | NT 10-Q：季报延迟披露公告
美股sec公告 ·  05/15 16:06
Moomoo AI 已提取核心信息
NexImmune, Inc. has notified the Securities and Exchange Commission (SEC) of a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company has cited a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements within the prescribed time frame. Despite the reduction, key management and scientific team members remain to maximize the value of NexImmune's business and assets. NexImmune expects to file the report within a five-day extension period allowed under SEC Rule 12b-25. The company anticipates that its cash and cash equivalents will remain similar to the previous quarter's amount of $3.2 million. It also expects a significant decrease in research and development expenses due to paused clinical trials, and a reduction in general and administrative expenses, leading to a substantially lower net loss and net loss per share compared to the first quarter of 2023. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
NexImmune, Inc. has notified the Securities and Exchange Commission (SEC) of a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company has cited a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements within the prescribed time frame. Despite the reduction, key management and scientific team members remain to maximize the value of NexImmune's business and assets. NexImmune expects to file the report within a five-day extension period allowed under SEC Rule 12b-25. The company anticipates that its cash and cash equivalents will remain similar to the previous quarter's amount of $3.2 million. It also expects a significant decrease in research and development expenses due to paused clinical trials, and a reduction in general and administrative expenses, leading to a substantially lower net loss and net loss per share compared to the first quarter of 2023. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
NexImmune, Inc.已通知美国证券交易委员会（SEC），延迟提交截至2024年3月31日的10-Q表季度报告。该公司表示，员工人数大幅减少，这使其在规定的时限内编制和审查财务报表的资源减少了。尽管有所减少，但关键管理层和科学团队成员仍在努力最大限度地提高NexImmune的业务和资产的价值。NexImmune预计将在美国证券交易委员会第12b-25条规定的五天延期内提交该报告。该公司预计，其现金和现金等价物将与上一季度的320万美元相似。它还预计，由于临床试验暂停，研发费用将大幅减少，一般和管理费用减少，从而与2023年第一季度相比，净亏损和每股净亏损将大大降低。这些前瞻性陈述受风险和不确定性的影响，实际结果可能存在重大差异。
NexImmune, Inc.已通知美国证券交易委员会（SEC），延迟提交截至2024年3月31日的10-Q表季度报告。该公司表示，员工人数大幅减少，这使其在规定的时限内编制和审查财务报表的资源减少了。尽管有所减少，但关键管理层和科学团队成员仍在努力最大限度地提高NexImmune的业务和资产的价值。NexImmune预计将在美国证券交易委员会第12b-25条规定的五天延期内提交该报告。该公司预计，其现金和现金等价物将与上一季度的320万美元相似。它还预计，由于临床试验暂停，研发费用将大幅减少，一般和管理费用减少，从而与2023年第一季度相比，净亏损和每股净亏损将大大降低。这些前瞻性陈述受风险和不确定性的影响，实际结果可能存在重大差异。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息